Equity Profile

AMGN

Amgen Inc.

Health CareBiotechnology$188.7B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:00 PM EDT

Amgen Beats on EPS, Stock Up 2.43%

Metric	Actual	Expected	Surprise
EPS	$5.15	$4.76	+8.88%
Revenue	N/A	$8.6B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Amgen Beats on EPS, Stock Up 2.43%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$5.15	$4.76	+8.88%
Revenue	N/A	$8.6B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Amgen's earnings report showed a strong performance on EPS, exceeding expectations by nearly 9%. This positive surprise contributed to a 2.43% increase in the stock price. However, the lack of revenue data and management commentary leaves some uncertainty about the overall business outlook.

Company Snapshot

Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.

$4.76

Revenue

Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.

$8.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen is known for its advancements in biologic medicines, which are crucial for treating conditions like cancer and autoimmune diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q4-2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. Despite the positive earnings surprise, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about Amgen's upcoming earnings, expecting solid EPS and revenue figures. The company has consistently beaten EPS estimates in recent quarters, which adds to the positive sentiment.

Bull Case

If Amgen continues its trend of beating EPS estimates, it could signal strong operational efficiency and product demand, potentially leading to a stock price increase.

Bear Case

Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about future growth, leading to a negative reaction in the stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$4.76

EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.

Revenue

$8.6B

Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $4.76?

A strong EPS performance could reinforce investor confidence and support a positive stock reaction.

What guidance will Amgen provide for future revenue growth?

Insights into future revenue expectations will be critical for assessing the company's growth trajectory and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Amgen's ability to sustain its earnings momentum, given the recent strong performance and potential for new product launches.

Supporting Evidence

Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Insider trading patterns show mixed signals, which could indicate uncertainty about future performance.

Key Risk

If EPS comes in below $4.50, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amgen can maintain its strong earnings performance amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $5.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $4.50 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±0.8%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating that traders expect volatility.

Options are pricing a 4.3% move, while the stock has averaged only 0.8% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.7%

30d HV

16.0%

Calls (166K)P/C Ratio: 0.65Puts (142K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests a potential stock increase of around 0.6%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally as investors reassess future growth.

Miss

If Amgen misses expectations, history suggests a potential decline of around 0.4%, raising concerns about future profitability.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Updates on competitive pressures in the biotechnology sector.
4Any changes in guidance for future quarters, especially regarding revenue growth.
5Management's view on market conditions and their potential impact on Amgen's performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Sanmina Corporation

Company Snapshot

Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.

$4.76

Revenue

Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.

$8.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q4-2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. Despite the positive earnings surprise, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Amgen continues its trend of beating EPS estimates, it could signal strong operational efficiency and product demand, potentially leading to a stock price increase.

Bear Case

Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about future growth, leading to a negative reaction in the stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$4.76

EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.

Revenue

$8.6B

Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $4.76?

A strong EPS performance could reinforce investor confidence and support a positive stock reaction.

What guidance will Amgen provide for future revenue growth?

Insights into future revenue expectations will be critical for assessing the company's growth trajectory and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Amgen's ability to sustain its earnings momentum, given the recent strong performance and potential for new product launches.

Supporting Evidence

Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Insider trading patterns show mixed signals, which could indicate uncertainty about future performance.

Key Risk

If EPS comes in below $4.50, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amgen can maintain its strong earnings performance amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $5.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $4.50 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±0.8%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating that traders expect volatility.

Options are pricing a 4.3% move, while the stock has averaged only 0.8% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.7%

30d HV

16.0%

Calls (166K)P/C Ratio: 0.65Puts (142K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests a potential stock increase of around 0.6%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally as investors reassess future growth.

Miss

If Amgen misses expectations, history suggests a potential decline of around 0.4%, raising concerns about future profitability.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Updates on competitive pressures in the biotechnology sector.
4Any changes in guidance for future quarters, especially regarding revenue growth.
5Management's view on market conditions and their potential impact on Amgen's performance.